2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-130071
    Iproplatin 62928-11-4 98%
    Iproplatin (CHIP) is an anti-cancer agent with reduced toxicity in testicular and ovarian cancers. The major reduced product of Iproplatin by glutathione is chloro-bis (isopropylamine) glutathionatoplatinum (II). Iproplatin is promising for research of Thrombocytopenia and a wide range of cancers.
    Iproplatin
  • HY-130226
    11-epi-PGE1 24570-01-2 98%
    11-epi-PGE1 (11β-Prostaglandin E1) is a less potent isomer of Prostaglandin E1 (HY-B0131). Prostaglandin E1 is a prostanoid receptor ligand.
    11-epi-PGE1
  • HY-130229
    (±)5,6-DHET lactone 213126-92-2 98%
    5,6-DiHET lactone ((±)5,6-DiHETrE lactone) is a lactonized form of 5,6-EET and 5,6-DiHET. In solution, 5(6)-EET degrades into 5(6)-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS.1 5,6-DiHET potently induces vasodilation of isolated canine coronary arterioles, with 41 and 100% inhibition occurring at 0.01 and 100 pM, respectively. It also induces vasodilation in isolated human microvessels and increases intracellular calcium levels in a dose-dependent manner, an effect that can be blocked by the nitric oxide scavenger L-NAME.
    (±)5,6-DHET lactone
  • HY-130272
    Anti-MI/R injury agent 1 2387506-35-4 98%
    Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats.
    Anti-MI/R injury agent 1
  • HY-130284
    NF864 69606-09-3 98%
    NF864 is a selectivelyP2X1 receptorinhibitor in human platelets.
    NF864
  • HY-130438
    EUK-118 186299-34-3 98%
    EUK-118 is an analog of EUK 8 and EUK 134 with reduced activity. EUK-118 exhibits superoxide dismutase (SOD) mimetic activity.
    EUK-118
  • HY-13047A
    rel-S-(+)-Mecamylamine hydrochloride 110691-49-1 98%
    rel-S-(+)-Mecamylamine hydrochloride is a known antihypertensive drug .
    rel-S-(+)-Mecamylamine hydrochloride
  • HY-130666
    Chlorambucyl-proline 81050-71-7 98%
    Chlorambucyl-proline is a chloroplatinyl amino acid derivative with inhibitory activity against bovine pulmonary vasoconstrictor enzyme. Chlorambucyl-proline reacts with the convertase in a 1:1 ratio, and the removal of its radiolabel indicates that the compound has an irreversible inhibitory effect on the enzyme activity. Chlorambucyl-proline binds to the aspartic acid or glutamic acid side chain of the enzyme by forming an ester bond, resulting in irreversible inactivation of the enzyme. The inactivation rate constant of chlororambucyl-proline increases in the pH range of 5-8, indicating that its effect on the enzyme activity is affected by the pH environment.
    Chlorambucyl-proline
  • HY-130673
    L-NABE 7672-27-7 98%
    L-NABE is a nitric oxide (NO) synthase inhibitor. L-NABE is also a potent endothelium dependent vasoconstrictor and inhibitor of relaxation.
    L-NABE
  • HY-131162
    Chymase 97501-92-3
    Chymase is a protein-digester enzyme found primarily in mast cells (MC), fibroblasts, and vascular endothelial cells. Chymase is released into the extracellular stroma in the context of inflammatory signals, tissue injury and cellular stress. Chymase is also involved in angiotensin II (Ang II) production, which is used in cardiovascular disease studies.
    Chymase
  • HY-131279
    Olmesartan ethyl ester 144689-23-6 98%
    Olmesartan ethyl ester (compound 11) is an Olmesartan impurity. Olmesartan (RNH-6270) is an angiotensin II receptor (AT1R) antagonist used to in the high blood pressure study.
    Olmesartan ethyl ester
  • HY-131395
    N-Acetyl-Leukotriene E4 80115-95-3 98%
    N-Acetyl-Leukotriene E4 (N-Acetyl-LTE4) is a metabolite of Leukotriene E4 (LTE4) (HY-113465), which is detected in bile and urine. N-Acetyl-Leukotriene E4 produces a vasoconstriction in the mesenteric vessels which led to reduction of blood flow to the gut.
    N-Acetyl-Leukotriene E4
  • HY-131453
    Mitochondrial respiration-IN-1 1352002-58-4 98%
    Mitochondrial respiration-IN-1 is a mitochondrial respiratory inhibitor. Mitochondrial respiration-IN-1 reduces platelet aggregation, adhesion, and platelet-induced coagulation responses. Mitochondrial respiration-IN-1 induces adaptive glycolysis, decreases mitochondrial membrane potential, selectively reduces ATP production derived from oxidative phosphorylation, and exerts bidirectional regulatory effects on cell proliferation. Mitochondrial respiration-IN-1 activates UPRmt and upregulates the expression of SDHA-1 and MT-CO1. Mitochondrial respiration-IN-1 restores metabolic homeostasis in type 2 diabetic mice. Mitochondrial respiration-IN-1 can be used to investigate diseases mediated by inappropriate platelet activation/aggregation and type 2 diabetes.
    Mitochondrial respiration-IN-1
  • HY-131566
    Amiquinsin hydrochloride monohydrate 7125-70-4 98%
    Amiquinsin hydrochloride monohydrate is a compound with hypotensive activity. Amiquinsin hydrochloride monohydrate is metabolized in vivo, and the major metabolite is 4-amino-6,7-dimethoxy-3-quinolinol hydrochloride hydrate.
    Amiquinsin hydrochloride monohydrate
  • HY-131696
    11-deoxy Prostaglandin F1α 37785-98-1 98%
    11-deoxy Prostaglandin F1α (11-deoxy PGF1α) is an analog of prostaglandin F1α, exhibits side effects on intestines and causes the uterine contraction. 11-deoxy Prostaglandin F1α exhibits activity as vasopressor and bronchoconstrictor.
    11-deoxy Prostaglandin F1α
  • HY-131729
    16-Phenoxy tetranor Prostaglandin A2 51639-10-2 98%
    16-Phenoxy tetranor Prostaglandin A2 is a metabolite of uprostone and an analog of the antifertility hormone PGF2α.
    16-Phenoxy tetranor Prostaglandin A2
  • HY-131896
    FR144420 162626-99-5 98%
    FR144420 (NOR4) is an orally active nitric oxide (NO)-releasing agent with vasodilatory and antiplatelet effects. FR144420 induces cGMP-mediated vasodilation and inhibits platelet aggregation. FR144420 is promising for research of cardiovascular diseases, particularly angina pectoris and coronary artery spasm.
    FR144420
  • HY-131987
    Ethacizine 33414-33-4 98%
    Ethacizine is an antiarrhythmic agent with inhibitory activity on sodium channels.
    Ethacizine
  • HY-13209S
    Ambrisentan-d10 1046116-27-1 98%
    Ambrisentan-d10 (BSF 208075-d10; LU 208075-d10) is the deuterium labled Ambrisentan (HY-13209). Ambrisentan is a selective ET type A receptor (ETAR) antagonist.
    Ambrisentan-d10
  • HY-132210
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane 116673-45-1 98%
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane (compound 6) is a platelet-activating factor receptor (PAFR) antagonist with a Ki of 0.3 µM.
    rel-(2R,4R)-2,4-Bis(3,4,5-trimethoxyphenyl)-1,3-dioxolane
Cat. No. Product Name / Synonyms Application Reactivity